Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    50,369.82
    +384.12 (+0.77%)
     

  • CMC Crypto 200

    1,316.11
    +39.13 (+3.06%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

FDA panel votes for more data before approval of AstraZeneca drug

Reuters - UK Focus

June 25 (Reuters) - An advisory panel to the U.S. Food and Drug Administration recommended on Wednesday that AstraZeneca (EUREX: AZNF.EX - news) Plc be required to submit further clinical data before its experimental ovarian cancer drug is approved.

The panel voted 11-2 that the company should complete a second trial to confirm results seen in a smaller trial which, while positive, were not robust enough to convince the committee that they could be reproduced.

Panel members also expressed concern about a potential increased risk of secondary cancers in patients receiving the drug, olaparib. The FDA is not obliged to follow the advice of its advisory panels but typically does so. (Reporting by Toni Clarke in Washington; Editing by Bill Trott)